BC3 Technologies
Biotechnology ResearchMaryland, United States2-10 Employees
BC3 Technologies, based in Baltimore, Maryland, is a small biotechnology research firm focused on antihemorrhagic products for medical, military, and consumer markets. The company employs a proprietary chitosan-based aerosol that can be applied to wounds and supports rapid clotting, with performance and cost comparable to existing products. The technology is described as stable and versatile, aiming for a broad range of applications. Its customers include healthcare providers, emergency responders, and other users seeking effective wound control. In September 2023, BC3 Technologies released a professional version of SEAL, its hemostatic wound spray, which has been adopted by police departments and EMS across the United States. In September 2024, the company announced a distribution partnership with First Aid Only to expand SEAL's reach.